Skip to content
Home
Our Science
Pipeline & Assets
Team & Investors
Careers
News & Resources
Connect
News
& Resources
Featured Stories
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
Read More
GlobeNewswire
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
Read More
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
Read More
News
Patient Resources
Videos
Publications & Presentations
All
Media Coverage
Press Releases
Media Coverage
|
Posted on 4.16.25
Siren community investment round featured in BiotechTV
Read More
Media Coverage
|
Posted on 4.16.25
Siren Biotechnology Opens Community Investment Round!
Read More
Media Coverage
|
Posted on 4.3.25
Siren CEO and Founder Dr. Nicole Paulk named in SFBT Women to Watch
Read More
Media Coverage
|
Posted on 4.3.25
Siren Biotechnology Presents at SXSW 2025
Read More
Press Releases
|
Posted on 3.4.25
Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders
Read More
Media Coverage
|
Posted on 1.9.25
Siren Biotechnology named 2025 Company to Watch by Slice of Healthcare
Read More
Media Coverage
|
Posted on 12.13.24
Siren CEO and Founder Dr. Nicole Paulk honored in Slice of Healthcare’s 50 Under 50 list
Read More
Media Coverage
|
Posted on 11.20.24
Siren Biotechnology awarded BioTech Breakthroughs Innovation of the Year Award
Read More
Press Releases
|
Posted on 11.18.24
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Read More
Media Coverage
|
Posted on 10.11.24
Siren CEO & Founder Dr. Nicole Paulk honored as one of the Most Influential Women in Bay Area Business
Read More
1
2
3
4
…
6
